Skip to main content
SpringerLink
Log in

Recent R&D Highlights

  • News & View
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Director of Clinical Research at the Institute for Drug Development in San Antonio, TX.

  2. Respective brandnames for: trastuzumab, Genentech/Roche; gefitinib, AstraZeneca; cetuximab, Bristol-Myers Squibb/Imclone Systems; erlotinib, Genentech/OSI Pharmaceuticals/Roche.

References

  1. Breaking from tradition in the design of phase II/III clinical trials [panel session]. 2005 American Society of Clinical Oncology Annual Meeting; 2005 May 13–17; Orlando (FL). Available from URL: http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-00930,00.asp/ac/1,1003,_12-002511-00_18-0034-00_19-00930,00.asp [Accessed 2005 Jun 20]

  2. Targeted oncologic therapies demand new approach to phase II/III trials. Pink Sheet 2005; 67 (23): 15

    Google Scholar 

  3. University of California, San Diego. Vaccine approach to treating Parkinson’s disease. Media release: 15 Jun 2005

    Google Scholar 

  4. Ludwig Institute for Cancer Research. Cancer research finds targets for new cholesterol-lowering therapies. Media release: 7 Jun 2005

    Google Scholar 

  5. Johns Hopkins University. New memory drug works best in com bination with older remedy. Media release: 9 Jun 2005

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 3, 14–15 (2005). https://doi.org/10.1007/BF03259643

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259643

Search

Navigation